- Germany
- /
- Life Sciences
- /
- XTRA:GXI
Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Gerresheimer AG (ETR:GXI) shareholders would be excited to see that the share price has had a great month, posting a 25% gain and recovering from prior weakness. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 22% in the last twelve months.
Following the firm bounce in price, given around half the companies in Germany have price-to-earnings ratios (or "P/E's") below 16x, you may consider Gerresheimer as a stock to potentially avoid with its 24.5x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.
There hasn't been much to differentiate Gerresheimer's and the market's earnings growth lately. One possibility is that the P/E is high because investors think this modest earnings performance will accelerate. If not, then existing shareholders may be a little nervous about the viability of the share price.
View our latest analysis for Gerresheimer
Is There Enough Growth For Gerresheimer?
There's an inherent assumption that a company should outperform the market for P/E ratios like Gerresheimer's to be considered reasonable.
If we review the last year of earnings, the company posted a result that saw barely any deviation from a year ago. Regardless, EPS has managed to lift by a handy 20% in aggregate from three years ago, thanks to the earlier period of growth. So it appears to us that the company has had a mixed result in terms of growing earnings over that time.
Looking ahead now, EPS is anticipated to climb by 30% per annum during the coming three years according to the analysts following the company. With the market only predicted to deliver 16% each year, the company is positioned for a stronger earnings result.
With this information, we can see why Gerresheimer is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
The Key Takeaway
Gerresheimer shares have received a push in the right direction, but its P/E is elevated too. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
As we suspected, our examination of Gerresheimer's analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. It's hard to see the share price falling strongly in the near future under these circumstances.
Don't forget that there may be other risks. For instance, we've identified 1 warning sign for Gerresheimer that you should be aware of.
If you're unsure about the strength of Gerresheimer's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
⢠Connect an unlimited number of Portfolios and see your total in one currency
⢠Be alerted to new Warning Signs or Risks via email or mobile
⢠Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:GXI
Gerresheimer
Provides medicine packaging, drug delivery devices, and solutions in Germany and internationally.
Fair value with moderate growth potential.
Similar Companies
Market Insights
Weekly Picks

The "Sleeping Giant" Stumbles, Then Wakes Up
Swiped Left by Wall Street: The BMBL Rebound Trade

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For
Recently Updated Narratives
The Real Power Behind Alphabetās Growth
RELX: The Quiet Compounder Powering Law, Science, and Risk Intelligence
Why CVSās Valuation Signals Opportunity
Popular Narratives

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

